Omega Diagnostics Group PLC (LSE:ODX) - Share price

Stock Report

Omega Diagnostics Group PLC ODX

Last Price

Day Change

As of 05/05/2021
16:35:17 BST | GBX
Minimum 15 Minutes Delay.

Last Close69.50p
Day Range71.00 - 75.00
Mkt Cap130.80Mil
52-Wk Range32.01 - 127.00
Yield %-

Share Price

Total Returns 05/05/2021

 Chg (%)  
More ...
Omega Diagnostics Group PLC-12.09 
FTSE 100 TR GBP4.75
More ...
Income Statement
Operating Profit-1.22-0.270.70
Net Profit-1.21-0.34-6.83
Reported EPS-0.99-0.30-4.84
Balance Sheet
Current Assets4.913.494.46
Non Current Assets17.9919.9914.38
Total Assets22.9023.4818.84
Current Liabilities2.762.312.34
Total Liabilities---
Total Equity17.1218.1913.61
Cash Flow
Operating Cash Flow-0.720.250.38
Net Change in Cash-0.620.010.03
Director Dealings
More ...
09/04/2021Sale of OptionMr. William E. Rhodes, III79.31300,000237,926.00
09/04/2021Exercise of OptionMr. William E. Rhodes, III15.25300,00045,750.00
25/02/2021Sale of OptionMr. William E. Rhodes, III91.12450,000410,018.00
25/02/2021Exercise of OptionMr. William E. Rhodes, III15.25450,00068,625.00

Company Profile

Omega Diagnostics Group PLC provides in-vitro diagnostics (IVD) products for use in hospitals, blood banks, clinics and laboratories and specializes in the areas of allergy and autoimmune, food intolerance and infectious diseases. It has three segments: The Allergy and autoimmune division specialise in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases; The Food intolerance division specialises in the research, development, and production of kits to aid the detection of immune reactions to food; and The Infectious disease division specialises in the research, development, production, and marketing of kits to aid the diagnosis of infectious diseases.


Medical Instruments & Supplies


FTSE AIM All-Share

Next Event 14/07/2021

Final Results
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
Op Mrgn0.07
EPS Grwth0.00
More ...
Record Datet.b.c.t.b.c.
More ...
Executive Director, Finance Director and Company SecretaryMr. Kieron Antony Harbinson
Executive Director, Sales and Marketing DirectorMr. Jagdeep Grewal
Non-Executive DirectorMr. William E. Rhodes, III
Non-Executive DirectorMr. Jeremy Howard Millard
Executive Director, Chief Executive OfficerMr. Colin King
Non-Executive Director, ChairmanDr. Simon Gordon Douglas
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.